Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Complex antibody profiling to predict clinical outcome in childhood ADS.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Raxone®/Catena® (idebenone)
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Interferon beta for secondary progressive multiple sclerosis.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis

Pages